CZC 54252 hydrochloride
Cat. No. 4534
Chemical Name: N-[-[[5-Chloro-2-[[2-methoxy-4-(4-m
Biological ActivityPotent inhibitor of leucine-rich repeat kinase 2 (LRRK2) (IC50 values are 1.28 nM and 1.85 nM for wild-type and G2019S mutant forms of LRRK2 respectively). Attenuates neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM).
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Ramsden et al (2011) Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem.Biol. 6 1021. PMID: 21812418.
Kramer et al (2012) Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem.Neurosci. 3 151. PMID: 22860184.
If you know of a relevant citation for this product please let us know.
Keywords: CZC 54252 hydrochloride, supplier, CZC54252, leucine-rich, repeat, kinase, 2, LRRK2, inhibitors, inhibits, potent, neuroprotective, neuronal, injury, parkinson's, parkinsons
Find multiple products by catalog number
New Products in this Area
CaM kinase II inhibitor; water soluble version of KN-93 (Cat. No. 1278).Bryostatin 3
Potent protein kinase C activatorGKA 50
Glucokinase activatorMRT 67307 dihydrochloride
Salt inducible kinase (SIK) inhibitorLDN 209929 dihydrochloride
Potent and selective haspin kinase inhibitorRKI 1447 dihydrochloride
Potent and selective ROCK inhibitor; antitumorLIMKi 3
Potent LIM kinase inhibitor; antitumorFRAX 486
Potent p21-activated kinase (PAK) inhibitor; brain penetrant and orally bioavailableBIX 02189
Selective MEK5 and ERK5 inhibitorTC Mps1 12
Potent and selective monopolar spindle 1 (Mps1) kinase inhibitor; orally activeGSK 2606414
Potent and selective PERK inhibitor; orally bioavailableAZ 20
Potent and selective ATR kinase inhibitor; antitumorAZD 7762 hydrochloride
Potent and selective ATP-competitive inhibitor of Chk1 and Chk2PHT 427
Dual Akt and PDK1 inhibitor; antitumorML 786 dihydrochloride
Potent Raf kinase inhibitor; orally bioavailableSenexin A
Cyclin-dependent kinase 8 (cdk8) inhibitorXL 388
Potent and selective mTOR inhibitor; antitumorPS 1145 dihydrochloride
Selective IKK inhibitor; orally active
November 15 - 19, 2014
Washington D.C., USA